摘要
Exenatide（synthetic exendin-4）, which has been approved by the Food and Drug Administration（FDA） for the adjunctive treatment of patients with type 2 diabetes, is an incretin mimetic agent. The development and validation of a RP-HPLC method for the quantification of the exenatide in poly（lactic-co-glycolic acid）（PLGA） microspheres is described. Separation was performed on a C4 column via a mobile phase consisting of ACN：KH2PO4（0.02 tool/L, pH=2.5） gradient elution from 30：70 to 45：55（volume ratio） in 30 min. Multi-diode array detection（DAD） appears to be most appropriate to evaluate the spectral purity of exenatide. The limits of detection and quantification of exenatide were 0.4 and 1.2 μg/mL, respectively. The calibration curve of exenatide was linear in a range of 0.025--0.2 mg/mL with a correlation coefficient of 0.9995. The results of validation study show that this method is specific, accurate（recovery〉95%）, precise（RSD〈2.0%） and robust.
Exenatide（synthetic exendin-4）, which has been approved by the Food and Drug Administration（FDA） for the adjunctive treatment of patients with type 2 diabetes, is an incretin mimetic agent. The development and validation of a RP-HPLC method for the quantification of the exenatide in poly（lactic-co-glycolic acid）（PLGA） microspheres is described. Separation was performed on a C4 column via a mobile phase consisting of ACN：KH2PO4（0.02 tool/L, pH=2.5） gradient elution from 30：70 to 45：55（volume ratio） in 30 min. Multi-diode array detection（DAD） appears to be most appropriate to evaluate the spectral purity of exenatide. The limits of detection and quantification of exenatide were 0.4 and 1.2 μg/mL, respectively. The calibration curve of exenatide was linear in a range of 0.025--0.2 mg/mL with a correlation coefficient of 0.9995. The results of validation study show that this method is specific, accurate（recovery〉95%）, precise（RSD〈2.0%） and robust.
基金
Supported by the Key Projects in the National Science & Technology Pillar Program in the Eleventh Five-year Plan Period,China(No.2008ZX10001-012)
